Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations

Bone Marrow Transplant. 2021 Jul;56(7):1710-1713. doi: 10.1038/s41409-021-01230-z. Epub 2021 Feb 24.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azacitidine / therapeutic use
  • Decitabine / pharmacology
  • Decitabine / therapeutic use
  • Humans
  • Immunotherapy, Adoptive
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Receptors, Chimeric Antigen*
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Receptors, Chimeric Antigen
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Decitabine
  • Azacitidine